BEAM Stock Price Today (October 2026) — Beam Therapeutics Inc. Analysis & Key Metrics 2026-10-20
Beam Therapeutics Inc. (BEAM) is trading at $24.93, up 3.06% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $52.15 (109.2% upside).
- Volatility is high (42.60% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-94.20% YoY) alongside competitive pressures in the Biotechnology space.
BEAM Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Beam Therapeutics Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $1.67B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+109.2% upside potential
Key Investor Questions About BEAM
What investors need to know before buying
Based on current market data, BEAM presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 51.83)
- Fundamentals say: Challenging (declining revenue trends)
BEAM's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BEAM investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $247.36M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, BEAM stock traded between $20.23 and $38.26 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 42.60% annualized volatility and β=2.21, the stock exhibits high sensitivity to market moves—making BEAM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Beam Therapeutics Insider Sold Shares Worth $1,188,745, According to a Recent SEC Filing
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative
Beam sues 2 biotechs, alleging theft of base editing trade secrets
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Latest TickZen Insights
All insights →No TickZen article on BEAM yet. Our newest analysis:
Explore More Analysis for BEAM
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 9, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) is currently trading at $24.93. The RSI (14-day) is at 51.8, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $52.15 implies 109.2% upside from current levels. Volatility is high at 42.6% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Beam Therapeutics Inc. (BEAM): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 2.26. Price-to-Sales is 15.97. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 13 analysts covering BEAM, the consensus price target is $52.15. This represents a 109.2% upside from the current price of $24.93. The range spans from a low target of $26.00 to a high target of $80.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Beam Therapeutics Inc. (BEAM) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Beam Therapeutics Inc. (BEAM) investors include: 1. High volatility (42.6% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-94.2% YoY), indicating potential business headwinds. 4. Elevated short interest (41.2% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Beam Therapeutics Inc.'s (BEAM) current debt and financial health profile: Total debt stands at $247.36M. The debt-to-equity ratio is 0.23x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 14.57, indicating strong short-term liquidity. The quick ratio is 14.25. The company holds $1.15B in cash and equivalents. Free cash flow is negative at -$241.84M, which could limit the company's ability to manage debt obligations.